8-K - Sutro Biopharma, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement On February 9, 2026, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting

Material Agreement

$13.98$110.0M$110.0M$251.4M

7.01

of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement dated February 9, 2026 5.1 Opinion of Fenwick & West LL

Exhibits Only

Source Document

Exhibits (4)

1.1

EX-1.1

5.1

EX-5.1

8-K

99.1

EX-99.1